2026年3月30日 (一) 14:38 imported>Raymon090

2026-03-30T14:38:13Z

新页面

{{Drugbox|IUPAC_name=<nowiki>(2S)-2-[[(E)-3-(4-chloro-2-fluorophenyl)prop-2-enoyl]amino]-N-[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]-3-phenylpropanamide</nowiki>|image=3CLpro-1_structure.png
|tradename=3CLpro-1|legal_US=Investigational drug|legal_status=|bioavailability=|metabolism=|elimination_half-life=|excretion=|CAS_number=2409054-43-7|PubChem=44578386|UNII=|ChemSpiderID=24697352|ChEMBL=477164

|C=25|H=25|Cl=1|F=1|N=3|O=4|molecular_weight=640.8|SMILES=C1CNC(=O)[C@@H]1C[C@@H](C=O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)/C=C/C3=C(C=C(C=C3)Cl)F|StdInChI=1S/C25H25ClFN3O4/c26-19-8-6-17(21(27)14-19)7-9-23(32)30-22(12-16-4-2-1-3-5-16)25(34)29-20(15-31)13-18-10-11-28-24(18)33/h1-9,14-15,18,20,22H,10-13H2,(H,28,33)(H,29,34)(H,30,32)/b9-7+/t18-,20-,22-/m0/s1|StdInChIKey=HXAHMXYAYHWWRI-ZCTWNQIISA-N}}

'''3CLpro-1'''是一种与[[芦平曲韦]]相关的[[抗病毒药物]]，作为[[3C样蛋白酶]][[蛋白酶抑制剂|抑制剂]]，最初开发用于治疗人类[[腸病毒71型|肠病毒71型]]。它是作为病毒酶3C样蛋白酶抑制剂开发的众多化合物中最有效的一种蛋白酶，体外[[半抑制浓度|IC<sub>50</sub>]]为200nM。它还显示出对[[嚴重急性呼吸系統綜合症|SARS]]和[[中東呼吸綜合症|MERS]]等[[冠状病毒]]疾病的活性，并且正在研究作为[[病毒性疾病]]COVID-19的潜在治疗剂。病毒性疾病[[COVID-19]]的治疗剂。<ref>{{Cite journal |last=Kuo |first=Chih-Jung |last2=Shie |first2=Jiun-Jie |last3=Fang |first3=Jim-Min |last4=Yen |first4=Guei-Rung |last5=Hsu |first5=John T. -A. |last6=Liu |first6=Hun-Ge |last7=Tseng |first7=Sung-Nain |last8=Chang |first8=Shih-Cheng |last9=Lee |first9=Ching-Yin |last10=Shih |first10=Shin-Ru |last11=Liang |first11=Po-Huang |title=Design, synthesis, and evaluation of 3C protease inhibitors as anti-enterovirus 71 agents |url=https://www.sciencedirect.com/science/article/pii/S0968089608005634 |journal=Bioorganic & Medicinal Chemistry |date=2008-08-01 |volume=16 |issue=15 |page=7388-7398 |doi=10.1016/j.bmc.2008.06.015 |issn=0968-0896 |pmc=7125518 |pmid=18583140 |access-date=2026-03-30}}</ref><ref>{{Cite journal |last=Zhou |first=Yanchen |last2=Vedantham |first2=Punitha |last3=Lu |first3=Kai |last4=Agudelo |first4=Juliet |last5=Carrion |first5=Ricardo |last6=Nunneley |first6=Jerritt W. |last7=Barnard |first7=Dale |last8=Pöhlmann |first8=Stefan |last9=McKerrow |first9=James H. |last10=Renslo |first10=Adam R. |last11=Simmons |first11=Graham |title=Protease inhibitors targeting coronavirus and filovirus entry |url=https://www.sciencedirect.com/science/article/pii/S0166354215000248 |journal=Antiviral Research |date=2015-04-01 |volume=116 |page=73-84 |doi=10.1016/j.antiviral.2015.01.011 |issn=0166-3542 |pmc=4774534 |pmid=25666761 |access-date=2026-03-30}}</ref><ref>{{Cite journal |last=Kumar |first=Vathan |last2=Shin |first2=Jin Soo |last3=Shie |first3=Jiun-Jie |last4=Ku |first4=Keun Bon |last5=Kim |first5=Chonsaeng |last6=Go |first6=Yun Young |last7=Huang |first7=Kai-Fa |last8=Kim |first8=Meehyein |last9=Liang |first9=Po-Huang |title=Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CLPro inhibitors |url=https://www.sciencedirect.com/science/article/pii/S0166354216305083 |journal=Antiviral Research |date=2017-05-01 |volume=141 |page=101-106 |doi=10.1016/j.antiviral.2017.02.007 |issn=0166-3542 |pmc=7113684 |pmid=28216367 |access-date=2026-03-30}}</ref><ref>{{Cite journal |last=Liu |first=Cynthia |last2=Zhou |first2=Qiongqiong |last3=Li |first3=Yingzhu |last4=Garner |first4=Linda V. |last5=Watkins |first5=Steve P. |last6=Carter |first6=Linda J. |last7=Smoot |first7=Jeffrey |last8=Gregg |first8=Anne C. |last9=Daniels |first9=Angela D. |last10=Jervey |first10=Susan |last11=Albaiu |first11=Dana |title=Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases |url=https://pubs.acs.org/doi/10.1021/acscentsci.0c00272 |journal=ACS Central Science |language=en |date=2020-03-25 |volume=6 |issue=3 |page=315-331 |doi=10.1021/acscentsci.0c00272 |issn=2374-7943 |pmc=10467574 |pmid=32226821 |access-date=2026-03-30}}</ref><ref name="pmid32022370">{{Cite journal |last=Morse |first=Jared S. |last2=Lalonde |first2=Tyler |last3=Xu |first3=Shiqing |last4=Liu |first4=Wenshe Ray |title=Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019‐nCoV |url=https://chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/cbic.202000047 |journal=ChemBioChem |language=en |date=2020-03-02 |volume=21 |issue=5 |page=731-738 |doi=10.1002/cbic.202000047 |issn=1439-4227 |pmc=7162020 |pmid=32022370 |access-date=2026-03-30}}</ref><ref>{{Cite journal |last=Zhang |first=Linlin |last2=Lin |first2=Daizong |last3=Kusov |first3=Yuri |last4=Nian |first4=Yong |last5=Ma |first5=Qingjun |last6=Wang |first6=Jiang |last7=von Brunn |first7=Albrecht |last8=Leyssen |first8=Pieter |last9=Lanko |first9=Kristina |last10=Neyts |first10=Johan |last11=de Wilde |first11=Adriaan |title=α-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment |url=https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01828 |journal=Journal of Medicinal Chemistry |language=en |date=2020-05-14 |volume=63 |issue=9 |page=4562-4578 |doi=10.1021/acs.jmedchem.9b01828 |issn=0022-2623 |access-date=2026-03-30}}</ref><ref>{{Cite journal |last=Zhang |first=Linlin |last2=Lin |first2=Daizong |last3=Sun |first3=Xinyuanyuan |last4=Curth |first4=Ute |last5=Drosten |first5=Christian |last6=Sauerhering |first6=Lucie |last7=Becker |first7=Stephan |last8=Rox |first8=Katharina |last9=Hilgenfeld |first9=Rolf |title=Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors |url=https://www.science.org/doi/10.1126/science.abb3405 |journal=Science |language=en |date=2020-04-24 |volume=368 |issue=6489 |page=409-412 |doi=10.1126/science.abb3405 |issn=0036-8075 |pmc=7164518 |pmid=32198291 |access-date=2026-03-30}}</ref>

== 另见 ==

* [[卡莫氟]]
* [[依布硒]]
* [[GC376]]
* [[GRL-0617]]
* [[芦平曲韦]]
* [[茶黄素双没食子酸酯]]

== 参考资料 ==
{{Reflist}}

[[Category:2-氟-4-氯苯基化合物]]
[[Category:抗病毒药物]]
[[Category:苄基化合物]]
[[Category:烯烃衍生物]]
[[Category:酰胺]]

3CLpro-1 - 版本历史

2026年3月30日 (一) 14:38 imported>Raymon090